Last 47 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -3.03 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 5.18 | 7.38 | 5.34 | 6.09 | 4.23 | 2.20 | 1.97 | 1.80 | 3.76 | 3.82 | 5.42 | 2.76 | 3.11 | 5.96 | 11.95 | 10.26 | 13.15 | 12.56 | 19.54 | 13.79 | 12.18 |
| — | +235.6% | +170.7% | +238.2% | +12.6% | -42.4% | -63.6% | -34.7% | +21.0% | -35.9% | -54.7% | -73.2% | -76.4% | -52.5% | -38.8% | -25.5% | +7.9% | +22.2% | +58.2% | +106.9% | +25.3% | |
| P/B Ratio | 3.84 | 4.20 | 3.15 | 3.58 | 3.95 | 2.03 | 1.26 | 1.09 | 1.70 | 1.84 | 2.22 | 1.03 | 1.09 | 1.89 | 3.16 | 3.22 | 3.33 | 2.90 | 4.08 | 3.97 | 2.88 |
| — | +106.4% | +149.6% | +227.9% | +132.0% | +10.2% | -43.4% | +5.6% | +57.0% | -2.6% | -29.5% | -67.9% | -67.4% | -34.6% | -22.6% | -18.8% | +15.6% | +36.1% | +78.8% | +111.9% | +42.6% | |
| P/FCF | — | — | — | — | — | 2.32 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 93.0% | 100.0% | 93.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 97.0% | 97.8% | 96.8% | 96.3% | 100.0% | 100.0% | 100.0% |
| — | 0.0% | -7.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | +3.1% | +2.2% | +3.3% | +3.8% | -3.0% | -2.2% | -3.2% | -3.7% | 0.0% | 0.0% | 0.0% | |
| Operating Margin | -130.7% | -120.0% | -69.1% | -60.5% | -121.6% | -103.2% | -164.3% | -138.8% | -204.4% | -134.6% | -192.1% | -193.8% | -163.9% | -194.3% | -221.7% | -127.3% | -133.1% | -167.1% | -180.8% | -110.0% | -143.1% |
| — | -16.4% | +58.0% | +56.5% | +40.5% | +23.3% | +14.5% | +28.4% | -24.7% | +30.7% | +13.3% | -52.3% | -23.1% | -16.3% | -22.6% | -15.7% | +6.9% | -6.7% | -22.6% | -183.9% | -70.9% | |
| Net Margin | -125.4% | -135.8% | -76.3% | -64.1% | -123.6% | -99.7% | -151.7% | -131.4% | -197.3% | -126.1% | -182.7% | -185.6% | -148.5% | -206.8% | -211.6% | -122.9% | -129.7% | -162.7% | -179.5% | -108.9% | -104.3% |
| — | -36.2% | +49.7% | +51.2% | +37.3% | +20.9% | +17.0% | +29.2% | -32.9% | +39.0% | +13.7% | -51.0% | -14.5% | -27.1% | -17.9% | -12.8% | -24.3% | -46.5% | -63.9% | -315.2% | +16.0% |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -84.6% | -17.9% | -10.8% | -12.5% | -26.0% | -21.1% | -22.1% | -18.5% | -20.8% | -14.4% | -17.4% | -16.4% | -12.4% | -15.4% | -13.2% | -9.3% | -8.0% | -9.1% | -9.0% | -7.7% | -6.0% |
| — | +15.2% | +51.2% | +32.6% | -25.1% | -46.9% | -26.7% | -13.3% | -67.8% | +6.6% | -31.8% | -75.5% | -54.7% | -69.3% | -46.1% | -21.3% | -32.8% | -61.7% | -82.1% | -318.7% | +4.0% | |
| ROA | -24.9% | -6.4% | -4.1% | -3.9% | -6.4% | -5.9% | -6.7% | -6.1% | -7.4% | -5.6% | -7.4% | -7.5% | -5.9% | -9.5% | -11.2% | -8.0% | -6.9% | -8.0% | -7.9% | -6.8% | -5.5% |
| — | -9.0% | +39.7% | +36.3% | +13.5% | -4.9% | +8.9% | +18.1% | -26.6% | +41.3% | +33.8% | +5.8% | +14.7% | -18.8% | -41.0% | -16.5% | -24.7% | -53.0% | -70.6% | -298.7% | +5.7% | |
| ROIC | -23.2% | -6.6% | -3.2% | -3.3% | -5.8% | -5.8% | -7.4% | -6.2% | -6.8% | -5.4% | -7.0% | -7.2% | -6.4% | -9.2% | -11.6% | -7.6% | -6.3% | -7.3% | -7.9% | -7.0% | -6.6% |
| — | -14.4% | +56.3% | +47.5% | +14.8% | -6.9% | -5.8% | +13.5% | -6.5% | +41.3% | +39.7% | +5.6% | -1.0% | -26.8% | -46.8% | -9.7% | +3.5% | -12.8% | -37.3% | -196.2% | -70.2% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 3.11 | 0.55 | 1.60 | 1.53 | 3.11 | 2.61 | 2.31 | 1.98 | 1.75 | 1.52 | 1.38 | 1.15 | 1.03 | 0.97 | 0.11 | 0.09 | 0.08 | 0.08 | 0.05 | 0.05 | 0.02 |
| — | -78.9% | -30.7% | -22.9% | +77.0% | +72.0% | +67.0% | +72.6% | +71.0% | +56.5% | +1167.0% | +1188.6% | +1135.8% | +1146.6% | +99.5% | +63.4% | +385.3% | +299.1% | +156.8% | +141.4% | -18.6% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 4.21 | 3.76 | 3.84 | 4.44 | 4.21 | 5.00 | 5.29 | 5.47 | 5.21 | 4.92 | 6.43 | 6.25 | 6.73 | 6.58 | 8.43 | 12.33 | 10.45 | 13.59 | 11.12 | 8.63 | 8.82 |
| — | -24.8% | -27.3% | -18.7% | -19.3% | +1.6% | -17.8% | -12.6% | -22.6% | -25.2% | -23.7% | -49.3% | -35.6% | -51.6% | -24.2% | +42.9% | +18.5% | +21.1% | -30.9% | -55.4% | -51.2% | |
| Quick Ratio | 4.21 | 3.76 | 3.84 | 4.44 | 4.21 | 5.00 | 5.29 | 5.47 | 5.21 | 4.92 | 6.43 | 6.25 | 6.73 | 6.58 | 8.43 | 12.33 | 10.45 | 13.59 | 11.12 | 8.63 | 8.82 |
| — | -24.8% | -27.3% | -18.7% | -19.3% | +1.6% | -17.8% | -12.6% | -22.6% | -25.2% | -23.7% | -49.3% | -35.6% | -51.6% | -24.2% | +42.9% | +18.5% | +21.1% | -30.9% | -55.4% | -51.2% | |
| Interest Coverage | -9.88 | -3.71 | -2.95 | -2.86 | -6.82 | -10.26 | -12.97 | -10.57 | -10.31 | -8.79 | -11.30 | -8.89 | -8.37 | -16.45 | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ENTA stock.
Enanta Pharmaceuticals, Inc.'s current P/E is -3.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Enanta Pharmaceuticals, Inc.'s current operating margin is -130.7%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Enanta Pharmaceuticals, Inc.'s business trajectory between earnings reports.